Fiche centre
Cleveland Clinic
Cleveland — United States
Essais liés58clinical trials
VilleClevelandlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05716100
Essais cliniques associés
58| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ozanimod | SEP | Phase 4 | NCT06529406 | COAST — Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod | RECRUITING |
| BrioVAD System | Insuffisance cardiaque | Non applicable | NCT06310031 | INNOVATE — Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | ACTIVE_NOT_RECRUITING |
| Hearo App | Insuffisance cardiaque | À vérifier | NCT06378632 | DETECT-HF — AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM | COMPLETED |
| OPTIMIZER® Integra CCM-D System (Treatment Arm) | Maladie coronarienne | Non applicable | NCT05855135 | INTEGRA-D — Assessment of Combined CCM and ICD Device in HFrEF | ACTIVE_NOT_RECRUITING |
| Cryoneurolysis | Cancer | Non applicable | NCT05444361 | Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy | ENROLLING_BY_INVITATION |
| INBRX-106 - Hexavalent OX40 agonist antibody | Cancer | Phase 1/2 | NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | RECRUITING |
| Botensilimab | Parkinson | Phase 2 | NCT05608044 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | ACTIVE_NOT_RECRUITING |
| VS-041 | Insuffisance cardiaque | Phase 1 | NCT07219511 | A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | ACTIVE_NOT_RECRUITING |
| Physiology-guided NCL PCI | Maladie coronarienne | Non applicable | NCT05701358 | COMPLETE-2 — Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease | ACTIVE_NOT_RECRUITING |
| Pumitamig | Cancer | Phase 1/2 | NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | RECRUITING |
| Empagliflozin | Maladie rénale chronique | Phase 3 | NCT07107945 | A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | ACTIVE_NOT_RECRUITING |
| WiSE System | Insuffisance cardiaque | Non applicable | NCT02922036 | SOLVE-CRT — Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients | ACTIVE_NOT_RECRUITING |
| CREXONT ER | Parkinson | Phase 4 | NCT07138560 | BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | RECRUITING |
| cemacabtagene ansegedleucel | SEP | Phase 2 | NCT06500273 | ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | RECRUITING |
| ZL-1310 | Cancer | Phase 3 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | RECRUITING |
| Ocrelizumab | SEP | Phase 2 | NCT04075266 | A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications | Parkinson | À vérifier | NCT07330258 | A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications | RECRUITING |
| Prasinezumab | Parkinson | Phase 2 | NCT04777331 | PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| Radical Prostatectomy | Cancer | Non applicable | NCT05027477 | CAPTAIN — A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer | ACTIVE_NOT_RECRUITING |
| Nerandomilast | Myopathies | Phase 3 | NCT07789015 | VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | NOT_YET_RECRUITING |
| AuroShell particle infusion | Cancer | Non applicable | NCT04240639 | An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue | UNKNOWN |
| ONO-2020 | Alzheimer | Phase 2 | NCT06881836 | A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | COMPLETED |
| The ParkCycle Study: Aerobic Exercise in PD | Parkinson | Non applicable | NCT01562496 | The ParkCycle Study: Aerobic Exercise in PD | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Anakinra | Épilepsie | Phase 3 | NCT07281027 | COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" | NOT_YET_RECRUITING |
| Phenotype, Genotype & Biomarkers in ALS and Related Disorders | Sclérose latérale amyotrophique | À vérifier | NCT02327845 | Phenotype, Genotype & Biomarkers in ALS and Related Disorders | ACTIVE_NOT_RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 4 | NCT06909214 | ADAPT-EARLY — A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | RECRUITING |
| Elranatamab | Cancer | Phase 3 | NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING |
| Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy | Épilepsie | Non applicable | NCT05283200 | Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy | ACTIVE_NOT_RECRUITING |
| Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy) | Épilepsie | Non applicable | NCT05954182 | Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy) | ACTIVE_NOT_RECRUITING |
| AAV9-hSyn1-miGRIK2 | Épilepsie | Phase 1/2 | NCT06063850 | GenTLE — AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease | Parkinson | Non applicable | NCT07748962 | Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease | NOT_YET_RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| RE104 for Injection | Sclérose latérale amyotrophique | Phase 2 | NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 3 | NCT06298552 | ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04252742 | EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |
| zorevunersen | Épilepsie | Phase 3 | NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | ACTIVE_NOT_RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT04462770 | ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | RECRUITING |
| RAP-219 | Épilepsie | Phase 3 | NCT07563881 | FOCUS 1 — Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | RECRUITING |
| CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease) | Alzheimer | Non applicable | NCT04748861 | CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease) | ACTIVE_NOT_RECRUITING |
| BMS-986368 | Alzheimer | Phase 2 | NCT06808984 | Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | RECRUITING |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| Renal Denervation (Symplicity Spyral™) | Hypertension | Non applicable | NCT05198674 | SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN | ACTIVE_NOT_RECRUITING |
| The Paradise® Renal Denervation Ultrasound System | Hypertension | Non applicable | NCT02649426 | RADIANCE-HTN — A Study of the ReCor Medical Paradise System in Clinical Hypertension | ACTIVE_NOT_RECRUITING |
| Early Highly Effective Therapies Group | SEP | Phase 4 | NCT03535298 | DELIVER-MS — Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | ACTIVE_NOT_RECRUITING |
| Activa™ PC and Percept™ PC Neurostimulation Systems | Épilepsie | NA | NCT03900468 | Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS) | TERMINATED |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |
| Amifampridine Phosphate | Myasthénie | Phase 3 | NCT03304054 | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG | COMPLETED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |